Anemia Management

Diagnosis and Classification

• Anemia can be classified into mild (Hb ≤11.9 g/dL and ≥10 g/dL), moderate (Hb ≤9.9 and ≥8.0 g/dL), and severe (Hb <8.0 g/dL) based on hemoglobin levels, as defined by the Annals of Oncology 1
• Anemia diagnosis requires hemoglobin thresholds of <13.5 g/dL in men and <12.0 g/dL in women, according to the American Journal of Kidney Diseases guidelines 2
• Macrocytic anemia (MCV > 100 fL) is considered to be related to B12/folate deficiency 3
• The following table summarizes laboratory parameters used to diagnose and classify anemia:

• C-reactive protein is useful to assess the contribution of inflammation to elevated ferritin levels and helps interpret iron studies in chronic disease, with the Centers for Disease Control and Prevention recommending its use 5
• Reticulocyte count is essential for evaluating bone marrow erythropoietic activity and helps classify anemia as due to decreased production or increased destruction/loss, as recommended by the American College of Physicians and the Centers for Disease Control and Prevention 5

Treatment

• Oral iron supplementation with 35-65 mg of elemental iron daily is recommended for iron deficiency anemia, with options including ferrous sulfate, ferrous fumarate, or ferrous gluconate, as recommended by the American College of Cardiology, the European Society of Cardiology, and the American Gastroenterological Association 6, 7, 8, 9, 10
• Treatment should continue for 3 months after hemoglobin normalizes to replenish iron stores, as recommended by the American Gastroenterological Association and the European Society of Cardiology 8, 11, 6, 9, 10
• Vitamin C supplementation can be considered to enhance absorption if response to oral iron is poor, as recommended by the European Society of Gastroenterology 8
• Parenteral iron is indicated for severe anemia (Hb < 7.5 g/dL), intolerance to oral iron, malabsorption conditions, or need for rapid correction, as stated by the European Association for the Study of the Liver 12
• Erythropoiesis-Stimulating Agents (ESAs) can be considered for patients with hemoglobin consistently < 10 g/dL after iron stores correction, and blood pressure should be monitored with each dose, as recommended by the American Society of Nephrology 13
• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines indicate that ESA therapy is recommended for patients with hemoglobin consistently <10 g/dL after iron stores correction, and for those with symptomatic anemia affecting quality of life 14

Monitoring and Follow-up

• Hemoglobin and red cell indices should be monitored every three months for one year after correction, and iron studies should be checked if hemoglobin or MCV falls below normal, as stated by the European Society of Gastroenterology 8
• For patients with GFR < 30 ml/min/1.73 m², hemoglobin should be checked at least every three months, as stated by the American Society of Nephrology 13
• All non-menstruating patients with iron deficiency anemia should undergo GI evaluation to rule out occult bleeding, according to the European Society of Gastroenterology 8
• Upper and lower GI endoscopy is recommended for men and postmenopausal women, as recommended by the European Society of Gastroenterology 8
• The National Kidney Foundation recommends initiating erythropoietin therapy in patients with anemia and chronic kidney disease when hemoglobin levels are consistently below 10 g/dL, after correcting iron deposits and treating other reversible causes of anemia 14
• The target hemoglobin level is 11 g/dL, with an acceptable range of 10-12 g/dL, as recommended by the National Kidney Foundation 14
• Hemoglobin levels above 13 g/dL should be avoided due to the increased risk of cardiovascular events, according to the National Kidney Foundation 15

Transfusion Therapy

• Blood transfusion is typically reserved for hemoglobin < 7.5 g/dL with clinical symptoms or hemodynamic instability, and a restrictive transfusion strategy (hemoglobin threshold of 7-8 g/dL) should be used in stable patients, according to the European Society of Medical Oncology 16
• The Annals of Internal Medicine recommends using a restrictive transfusion strategy (hemoglobin threshold of 7-8 g/dL) in hospitalized patients with coronary heart disease 17
• The National Comprehensive Cancer Network recommends immediate PRBC transfusion for symptomatic patients, and consideration of transfusion for patients with cardiovascular, pulmonary, or cerebrovascular comorbidities, or those with progressive decline in Hb despite treatment 4
• One unit of PRBC typically increases Hb by approximately 1 g/dL, and transfusion decisions should not be based solely on Hb threshold 4

Special Populations

• Pregnant women, infants, and elderly are at higher risk for iron deficiency, and athletes may have increased iron requirements, according to the World Health Organisation, with a strength of evidence level of high 18
• Early detection and treatment of iron deficiency in children is crucial for preventing negative impacts on growth, cognitive development, and immune function, according to the Centers for Disease Control and Prevention (CDC) 19

Common Pitfalls

• Overlooking multiple concurrent causes of anemia, especially in elderly patients, is a common pitfall, as noted in Gut 9
• Failing to consider inflammation's effect on ferritin interpretation can lead to misdiagnosis, as described in the Journal of Crohn's and Colitis 18
• Not investigating GI blood loss in non-menstruating patients with iron deficiency is another common mistake, as reported in MMWR Recommendations and Reports 19
• Attributing iron deficiency solely to menstrual loss without proper GI investigation is a common pitfall, as warned by the Gut society 8, 9
• Inadequate iron replacement duration and overlooking functional iron deficiency are common mistakes, as cautioned by the Gut society and the American Society of Hematology 8, 20